(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(0.11%) $83.66
(-1.16%) $1.619
(0.30%) $2 349.60
(-0.43%) $27.52
(0.42%) $924.40
(0.32%) $0.935
(0.67%) $11.02
(0.13%) $0.800
(-0.07%) $92.11
4.96% $ 1.270
Live Chart Being Loaded With Signals
Veru Inc., an oncology biopharmaceutical company, focuses on developing medicines for the management of cancers. Its commercial products comprise FC2 female condom/internal condom for the dual protection against unintended pregnancy and the transmission of sexually transmitted infections for ministries of health, government health agencies, U...
Stats | |
---|---|
Объем за сегодня | 1.28M |
Средний объем | 2.42M |
Рыночная капитализация | 185.90M |
EPS | $0 ( 2024-02-08 ) |
Дата следующего отчета о доходах | ( $-0.0600 ) 2024-05-09 |
Last Dividend | $0.0700 ( 2014-04-28 ) |
Next Dividend | $0 ( N/A ) |
P/E | -1.810 |
ATR14 | $0.00400 (0.32%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-10-02 | Rankowitz Michael L | Buy | 90 000 | Common Stock Option |
2023-10-02 | Eisenberger Mario | Buy | 70 000 | Common Stock Option |
2023-10-02 | Lu Lucy | Buy | 80 000 | Common Stock Option |
2023-10-02 | Hyun Grace | Buy | 60 000 | Common Stock Option |
2023-05-09 | Greco Michele | Buy | 104 000 | Common Stock Option |
INSIDER POWER |
---|
94.70 |
Last 100 transactions |
Buy: 7 521 942 | Sell: 795 000 |
Объем Корреляция
Veru Inc Корреляция
10 Самые положительные корреляции | |
---|---|
AGLE | 0.927 |
CNSP | 0.911 |
STER | 0.91 |
PRTK | 0.91 |
AZYO | 0.906 |
TCX | 0.895 |
TTGT | 0.894 |
HCDIP | 0.891 |
TFFP | 0.885 |
INTZ | 0.879 |
10 Самые отрицательные корреляции | |
---|---|
LWAC | -0.95 |
FANH | -0.894 |
AGFS | -0.892 |
IMRA | -0.883 |
TGLS | -0.867 |
PTMN | -0.864 |
USLB | -0.862 |
LYTS | -0.859 |
SLGN | -0.856 |
SEDG | -0.852 |
Вы знали?
Корреляция - это статистический показатель, описывающий связь между двумя переменными. Он изменяется от -1 до 1, где -1 указывает на идеальную отрицательную корреляцию (при увеличении одной переменной другая уменьшается), 1 указывает на идеальную положительную корреляцию (при увеличении одной переменной другая увеличивается), а 0 указывает на отсутствие корреляции (между переменными нет связи).
Корреляцию можно использовать для анализа связи между любыми двумя переменными, не только акциями. Она широко используется в таких областях, как финансы, экономика, психология и т. д.
Veru Inc Корреляция - Валюта/Сырье
Veru Inc Финансовые показатели
Annual | 2023 |
Выручка: | $16.30M |
Валовая прибыль: | $7.57M (46.43 %) |
EPS: | $-1.100 |
FY | 2023 |
Выручка: | $16.30M |
Валовая прибыль: | $7.57M (46.43 %) |
EPS: | $-1.100 |
FY | 2022 |
Выручка: | $39.35M |
Валовая прибыль: | $30.59M (77.73 %) |
EPS: | $-1.050 |
FY | 2021 |
Выручка: | $61.26M |
Валовая прибыль: | $47.93M (78.24 %) |
EPS: | $0.100 |
Financial Reports:
No articles found.
Veru Inc Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $0.0500 | 2010-01-27 |
Last Dividend | $0.0700 | 2014-04-28 |
Next Dividend | $0 | N/A |
Payout Date | 2014-05-07 | |
Next Payout Date | N/A | |
# dividends | 18 | -- |
Total Paid Out | $1.040 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 1.68 | -- |
Div. Sustainability Score | 0 | |
Div.Growth Potential Score | 0 | |
Div. Directional Score | 0 | -- |
Year | Amount | Yield |
---|---|---|
2010 | $0.200 | 4.14% |
2011 | $0.200 | 3.50% |
2012 | $0.230 | 4.87% |
2013 | $0.270 | 3.69% |
2014 | $0.140 | 1.67% |
2015 | $0 | 0.00% |
2016 | $0 | 0.00% |
2017 | $0 | 0.00% |
2018 | $0 | 0.00% |
2019 | $0 | 0.00% |
2020 | $0 | 0.00% |
2021 | $0 | 0.00% |
2022 | $0 | 0.00% |
2023 | $0 | 0.00% |
2024 | $0 | 0.00% |
The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
SLVO | Dividend Royal | 2023-11-20 | Monthly | 12 | 10.77% | 8.50 |
QYLD | Dividend Royal | 2023-11-20 | Monthly | 11 | 7.50% | 8.50 |
PSEC | Dividend Royal | 2023-12-26 | Monthly | 21 | 7.04% | 8.50 |
GAIN | Dividend Royal | 2023-12-04 | Monthly | 20 | 8.19% | 8.50 |
GLDI | Dividend Royal | 2023-11-20 | Monthly | 12 | 7.15% | 8.50 |
OXLC | Dividend Royal | 2023-12-14 | Monthly | 14 | 10.00% | 8.50 |
OXSQ | Dividend Diamond | 2023-12-14 | Monthly | 21 | 9.10% | 8.50 |
HRZN | Dividend King | 2023-12-18 | Monthly | 15 | 6.60% | 8.45 |
USOI | Dividend Royal | 2023-11-20 | Monthly | 8 | 16.70% | 8.28 |
PFLT | Dividend King | 2023-11-15 | Monthly | 14 | 6.50% | 8.27 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -4.05 | 1.500 | -10.00 | -10.00 | [0 - 0.5] |
returnOnAssetsTTM | -0.801 | 1.200 | -10.00 | -10.00 | [0 - 0.3] |
returnOnEquityTTM | -2.14 | 1.500 | -10.00 | -10.00 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 3.21 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 2.58 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 2.44 | 1.500 | 10.00 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.133 | -1.500 | 7.78 | -10.00 | [0 - 0.6] |
interestCoverageTTM | -36.67 | 1.000 | -10.00 | -10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | -0.591 | 2.00 | -0.197 | -0.394 | [0 - 30] |
freeCashFlowPerShareTTM | -0.595 | 2.00 | -0.298 | -0.595 | [0 - 20] |
debtEquityRatioTTM | 0.208 | -1.500 | 9.17 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.503 | 1.000 | 4.95 | 4.95 | [0.2 - 0.8] |
operatingProfitMarginTTM | -3.96 | 1.000 | -10.00 | -10.00 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | -5.53 | 1.000 | -10.00 | -10.00 | [0.2 - 2] |
assetTurnoverTTM | 0.198 | 0.800 | -2.02 | -1.612 | [0.5 - 2] |
Total Score | -1.265 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -1.980 | 1.000 | -0.301 | 0 | [1 - 100] |
returnOnEquityTTM | -2.14 | 2.50 | -10.00 | -10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -0.595 | 2.00 | -0.198 | -0.595 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -0.591 | 2.00 | -0.197 | -0.394 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 0.416 | 1.500 | -0.561 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | -3.74 | 1.000 | -10.00 | 0 | [0.1 - 0.5] |
Total Score | -2.19 |
Veru Inc
Veru Inc., an oncology biopharmaceutical company, focuses on developing medicines for the management of cancers. Its commercial products comprise FC2 female condom/internal condom for the dual protection against unintended pregnancy and the transmission of sexually transmitted infections for ministries of health, government health agencies, U.N. agencies, nonprofit organizations, and commercial partners. The company's development drug candidates include Enobosarm, an oral selective androgen receptor agonist that is in phase III clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; Sabizabulin, which is phase IIb clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; Enobosarm + abemaciclib combination therapy, which is in phase III clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; and Sabizabulin + enobosarm combination therapy, an oral targeted cytoskeleton disruptor plus selective androgen receptor agonist, which is in phase II clinical trial for the treatment of metastatic triple negative breast cancer. Its drug candidates also comprise Sabizabulin, which is in Phase II clinical trial for the treatment of metastatic castration and androgen receptor targeting agent resistant prostate cancer; VERU-100, a GnRH antagonist peptide injection, which is in Phase II clinical trial for the treatment of advanced hormone sensitive prostate cancer; Zuclomiphene Citrate, which is in Phase II clinical trial for treating hot flashes; and Sabizabulin, which is in phase III clinical trial for the treatment of SARS-CoV-2 in subjects at high risk for acute respiratory distress syndrome. In addition, the company is advancing a new drug formulation for the treatment of men with lower urinary tract symptoms from an enlarged prostate. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.
О Торговые сигналы
Данные торговые сигналы, представленные на этой странице, помогают определить, когда следует ПОКУПАТЬ или ПРОДАВАТЬ NA. Сигналы имеют задержку более 1 минуты. Пожалуйста, примите во внимание, что существует вероятность ошибки или неточностей в силу различных микро и макро факторов влияющих на фондовые рынки.
Данные тор“о”ые сигна“ы не являются определен“ыми, и getagraph.com не несет ответственности за какие-либо действия, предпринятые в от“ошении этих сигналов, как описано в Terms of Use. Сигналы основаны на широком спектре индикаторов технического анализа